A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Phase 3

Recruiting

• Conditions: Autosomal Recessive Polycystic Kidney Disease (ARPKD)
• Interventions: Drug: Tolvaptan (OPC-41061)

• Registration Number: NCT04786574
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The primary objective of this study is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)

Detailed Description

Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 3), a closely related indication to ARPKD, as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV).

The trial will be the first trial of tolvaptan in a pediatric ARPKD population.

Participants in this study will be assigned to tolvaptan for 24 months and closely monitored over the course of the study.

Study Timeline

• Study First Submitted: 2021-02-19
• Study First Submitted QC: 2021-03-03
• Study First Posted: 2021-03-08
• Study Start: 2022-07-01
• Status Verified: 2023-08
• Last Update Submitted: 2023-09-14
• Last Update Posted: 2023-09-15
• Primary Completion: 2027-10-11
• Study Completion: 2027-10-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male or female subjects between 28 days and < 12 weeks of age, inclusive at the time of enrollment.

2. Must have clinical and imaging features that are consistent with a diagnosis of ARPKD with all the following characteristics:

   • Nephromegaly (> 2 standard deviations from age appropriate standard via ultrasound)
   • Multiple renal cysts
   • History of oligohydramnios or anhydramnios

3. Ability for parent or guardian to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.

Read More

Exclusion Criteria

1. Premature birth (≤ 32 weeks gestational age)
2. Anuria or RRT, defined as intermittent or continuous hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or history of kidney transplantation
3. Evidence of syndromic conditions associated with renal cysts (other than ARPKD)
4. Abnormal liver function tests including ALT and AST, > 1.2 × ULN
5. Parents with renal cystic disease
6. Need for chronic diuretic use
7. Cannot be monitored for fluid balance
8. Has or at risk of having sodium and potassium electrolyte imbalances
9. Has or at risk of having significant hypovolemia as determined by investigator
10. Clinically significant anemia, as determined by investigator
11. Severe systolic dysfunction defined as ejection fraction < 14%
12. Serum sodium levels < 130 mmol/L or >145 mmol/L
13. Taking any other experimental medications
14. Require ventilator support
15. Taking medications known to induce CYP3A4
16. Having an infection including viral that would require therapy disruptive to IMP dosing
17. Platelet count <50,000 µL
18. Significant Portal Hypertension
19. Bladder dysfunction or difficulty voiding
20. Taking vasopressin agonist
21. Having concomitant illness or taking medications that are likely to confound endpoint assessments.
22. History of cholangitis
23. Received or scheduled to receive a liver transplant

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tolvaptan (OPC-41061)	Tolvaptan (OPC-41061)	-

Primary Outcome Measures

Name	Time	Method
The percentage of subjects that will have Renal Replacement Therapy (RRT) by 1 year of age.	From Enrollment to 1 year of age

Secondary Outcome Measures

Name	Time	Method
Rate of change of eGFR by Schwartz formula from pre-treatment to after 2 years of treatment	From Enrollment to 2 years of age
Palatability of the suspension formulation as assessed by a parent questionnaire immediately after and within 15-20 minutes after the first oral dose	From Enrollment to 2 years of age
Acceptance of the suspension formulation as assessed by a parent questionnaire immediately after and within 15-20 minutes after the first oral dose	From Enrollment to 2 years of age

Trial Locations

Locations (18)

Johns Hopkins Pediatric Specialty Clinic; 🇺🇸 Baltimore, Maryland, United States

Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatology; 🇺🇸 Chicago, Illinois, United States

Great Ormond Street; 🇬🇧 London, United Kingdom

Emory University; 🇺🇸 Atlanta, Georgia, United States

Hospital Universitari Vall D Hebron; 🇪🇸 Barcelona, Spain

University Hospital of Cologne; 🇩🇪 Cologne, Nordrhein-Westfalen, Germany

Universitat de Barcelona - Hospital Sant Joan de Deu Barcelona (HSJDB); 🇪🇸 Barcelona, Spain

UZ Leuven; 🇧🇪 Leuven, Belgium

Hospital Universitario Virgen del Rocio; 🇪🇸 Sevilla, Spain

Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa; 🇵🇱 Białystok, Poland

Instytut "Pomnik - Centrum Zdrowia Dziecka"; 🇵🇱 Warszawa, Poland

Children's National Medical Center; 🇺🇸 Washington, District of Columbia, United States

Universitair Ziekenhuis Gent; 🇧🇪 Gent, Oost-Vlaanderen, Belgium

C.S. Mott Children's Hospital; 🇺🇸 Ann Arbor, Michigan, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Cincinnati Children's Hospital; 🇺🇸 Cincinnati, Ohio, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Primary Children's Hospital; 🇺🇸 Salt Lake City, Utah, United States